News Conference News ACC 2025 Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI Caitlin E. Cox March 30, 2025
News Opinion Editor's Corner ACC 2025 What’s Going to Be Hot at ACC 2025? Michael O'Riordan March 26, 2025
News Conference News ACC 2024 IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM Caitlin E. Cox April 15, 2024
News Conference News ACC 2023 Wearable Device Helps HF Patients Avoid Coming Back to the Hospital: BMAD Caitlin E. Cox March 06, 2023
News Conference News ACC 2023 Too Many HF Patients Exiting Rural Hospitals Miss Out on Endorsed Therapies Caitlin E. Cox February 23, 2023
News Conference News ACC 2022 What’s Going to Be Hot at ACC 2022, In Person or Virtual Shelley Wood March 28, 2022
News Conference News ACC 2021 REHAB-HF: Tailored Cardiac Rehab Promotes Physical Function After Hospital Stay Caitlin E. Cox May 16, 2021
News Conference News ACC 2018 Urgent/Emergent TAVR: Risky but Rewarding, TVT Registry Data Hint Caitlin E. Cox March 19, 2018
News Conference News ACC 2017 ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More Shelley Wood March 10, 2017